Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature…

Overview of attention for article published in Frontiers in immunology, August 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 50,414 followers.

Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review: Background, Patients… https://t.co/aNWeirxT3o #immu

10 Aug 2022

Reply Repost Favourite

New Research: Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review: Background Patients… https://t.co/7Jd

09 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.